Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer

Abstract

A combination of encorafenib, cetuximab, and binimetinib resulted in significantly longer overall survival and a higher response rate than standard therapy in patients with metastatic colorectal cancer with the <i>BRAF</i> V600E mutation. (Funded by Array BioPharma and others; BEACON CRC ClinicalTrials.gov number, NCT02928224; EudraCT number, 2015-005805-35.).

Keywords

Affiliated Institutions

• KU Leuven BE
• Odense University Hospital DK
• Vall d'Hebron Institute of Oncology
• University of Ulsan KR
• The Netherlands Cancer Institute NL
• Hospital General Universitario Gregorio Marañón ES
• First Pavlov State Medical University of St. Petersburg RU
• West Cancer Center US
• Hammersmith Hospital GB
• University College London GB
• National Institute for Health Research GB
• The University of Texas MD Anderson Cancer Center US
• University of Campania "Luigi Vanvitelli" IT
• The Christie NHS Foundation Trust GB
• Istituto Oncologico Veneto IT
• Peter MacCallum Cancer Centre AU
• Oslo University Hospital
• Sarah Cannon Research Institute GB
• Universitair Ziekenhuis Leuven BE
• Hebron University PS
• Array BioPharma (United States) US
• Imperial College London GB
• Ulsan College KR
• London Cancer GB
• Cancer Institute (WIA) IN
• National Cancer Center Hospital East JP
• Memorial Sloan Kettering Cancer Center US
• Asan Medical Center KR

Related Publications